Orvosi Hetilap
Volume/Issue:
Volume 149: Issue 20
Anti-TNF-α therapy in ulcerative colitis
Authors: Péter László Lakatos 1 and László Lakatos 2
View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar I. Belgyógyászati Klinika Budapest Korányi S. u. 2/A 1083
  • 2 Csolnoky Ferenc Megyei Kórház I. Belgyógyászati Osztály Veszprém
DOI:
https://doi.org/10.1556/oh.2008.28360
Page Count:
921–927
Publication Date:
01 May 2008
Online Publication Date:
08 May 2008
Article Category:
Research Article
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00
Purchase Online Subscription

  • Purchase article

    USD  $25.00

  • 1 year subscription (Individual Only)

    USD  $1,070.00

A colitis ulcerosa kezelését meghatározó legfontosabb tényezők a betegség kiterjedése és súlyossága. Az enyhe és középsúlyos betegek nagy többsége ma is a hagyományos gyógyszereket kapja (orális-topicalis 5-ASA, sulfasalazin). A hagyományos terápiára (szteroid, azathioprin, 5-ASA) rezisztens és a súlyos, akut colitis ulcerosa kezelése ugyanakkor nincs megoldva. Az újabb adatok alapján az infliximab indukciós vagy fenntartó kezelés formájában mindkét betegcsoportban hatékony kezelési alternatívát jelenthet, így az esetek egy részében elkerülhetővé válik a colectomia. Az összefoglalóban a szerzők colitis ulcerosában az anti-TNF-α-kezeléssel kapcsolatos eredményeket foglalták össze.

  • Lakatos, L., Lakatos, P. L.: A gyulladásos bélbetegségek etiopatogenezise. Orv. Hetil., 2003, 144 , 1853–1860.

    Lakatos P. L. , 'A gyulladásos bélbetegségek etiopatogenezise ' (2003 ) 144 Orv. Hetil. : 1853 -1860.

    • Search Google Scholar

  • Silverberg, M. S., Satsangi, J., Ahmad, T. és mtsai: Toward an integrated clinical, molecular, and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can. J. Gastroenterol., 2005, 19 (Suppl A) , 5A–36A.

    Ahmad T. , 'Toward an integrated clinical, molecular, and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology ' (2005 ) 19 Can. J. Gastroenterol. : 5A -36A.

    • Search Google Scholar

  • Lakatos, L., Lakatos, P. L.: A gyulladásos bélbetegségek gyógyszeres kezelése II. Colitis ulcerosa. Orv. Hetil., 2007, 148 , 1163–1170.

    Lakatos P. L. , 'A gyulladásos bélbetegségek gyógyszeres kezelése II. Colitis ulcerosa ' (2007 ) 148 Orv. Hetil. : 1163 -1170.

    • Search Google Scholar

  • European Federation of Crohn’s and Ulcerative Colitis Associations: Results from the EFCCA Pan-European survey of Crohn’s disease and ulcerative colitis patients. Available at http://www.efcca.org/final_pan_eu_survey_fact_sheet.pdf , 2005

  • Lakatos, P. L., Lakatos, L.: A TNF-α-ellenes antitest-terápia Crohn-betegségben. LAM, 2007, 17 , 529–536.

    Lakatos L. , 'A TNF-α-ellenes antitest-terápia Crohn-betegségben ' (2007 ) 17 LAM : 529 -536.

    • Search Google Scholar

  • Papadakis, K. A., Targan, S. R.: Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology, 2000, 119 , 1148–1157.

    Targan S. R. , 'Tumor necrosis factor: biology and therapeutic inhibitors ' (2000 ) 119 Gastroenterology : 1148 -1157.

    • Search Google Scholar

  • Bauditz, J., Haemling, J., Ortner, M. és mtsai: Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn’s disease. Gut, 1997, 40 , 470–474.

    Ortner M. , 'Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn’s disease ' (1997 ) 40 Gut : 470 -474.

    • Search Google Scholar

  • Mouser, J. F., Hyams, J. S.: Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn’s disease. Clin. Ther., 1999, 21 , 932–942.

    Hyams J. S. , 'Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn’s disease ' (1999 ) 21 Clin. Ther. : 932 -942.

    • Search Google Scholar

  • ven Hove, T., van Montfrans, C., Peppelenbosch, M. P. és mtsai: Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s disease. Gut, 2002, 50 , 206–211.

    Peppelenbosch M. P. , 'Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s disease ' (2002 ) 50 Gut : 206 -211.

    • Search Google Scholar

  • Di Sabatino, A., Ciccocioppo, R., Cinque, B. és mtsai: Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn’s disease. Gut, 2004, 53 , 70–77.

    Cinque B. , 'Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn’s disease ' (2004 ) 53 Gut : 70 -77.

    • Search Google Scholar

  • Danese, S., Sans, M., Scaldaferri, F. és mtsai: TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn’s disease. J. Immunol., 2006, 176 , 2617–2624.

    Scaldaferri F. , 'TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn’s disease ' (2006 ) 176 J. Immunol. : 2617 -2624.

    • Search Google Scholar

  • Di Sabatino, A., Ciccocioppo, R., Benazzato, L. és mtsai: Infliximab downregulates basic fibroblast growth factor and vascular endothelial growth factor in Crohn’s disease patients. Aliment. Pharmacol. Ther., 2004, 19 , 1019–1024.

    Benazzato L. , 'Infliximab downregulates basic fibroblast growth factor and vascular endothelial growth factor in Crohn’s disease patients ' (2004 ) 19 Aliment. Pharmacol. Ther. : 1019 -1024.

    • Search Google Scholar

  • Rutgeerts, P., Sandborn, W. J., Feagan, B. G. és mtsai: Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med., 2005, 353 , 2462–2476.

    Feagan B. G. , 'Infliximab for induction and maintenance therapy for ulcerative colitis ' (2005 ) 353 N. Engl. J. Med. : 2462 -2476.

    • Search Google Scholar

  • Lawson, M. M., Thomas, A. G., Akobeng, A. K.: Tumor necrosis factor alpha blocking agents for inducing remission in ulcerative colitis. Cochrane Database Syst. Rev., 2006, 3 , CD0005112.

    Akobeng A. K. , 'Tumor necrosis factor alpha blocking agents for inducing remission in ulcerative colitis ' (2006 ) 3 Cochrane Database Syst. Rev. : CD0005112 -.

    • Search Google Scholar

  • Gisbert, J. P., Gonzalez-Lama, Y., Mate, J.: Systematic review: infliximab therapy in ulcerative colitis. Aliment. Pharmacol. Ther., 2007, 25 , 19–37.

    Mate J. , 'Systematic review: infliximab therapy in ulcerative colitis ' (2007 ) 25 Aliment. Pharmacol. Ther. : 19 -37.

    • Search Google Scholar

  • Rutgeerts, P., Vermeire, S., Van Asche, G.: Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut, 2007, 56 , 453–455.

    Asche G. , 'Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? ' (2007 ) 56 Gut : 453 -455.

    • Search Google Scholar

  • Rubin, D. T., Huo, D., Rothe, J. A. és mtsai: Increased degree of histological inflammation predicts colectomy and hospitalization in patients with ulcerative colitis. Gastroenterology, 2007, 132 (Suppl.) , O103.

    Rothe J. A. , 'Increased degree of histological inflammation predicts colectomy and hospitalization in patients with ulcerative colitis ' (2007 ) 132 Gastroenterology : O103 -.

    • Search Google Scholar

  • Rubin, D. T., Huo, D., Rothe, J. A. és mtsai: Increased inflammatory activity is an independent risk factor for dysplasia and colorectal cancer in ulcerative colitis: a case-control analysis with blinded prospective pathology review. Gastroenterology, 2006, 130 (Suppl.) , O14.

    Rothe J. A. , 'Increased inflammatory activity is an independent risk factor for dysplasia and colorectal cancer in ulcerative colitis: a case-control analysis with blinded prospective pathology review ' (2006 ) 130 Gastroenterology : O14 -.

    • Search Google Scholar

  • Kornbluth, A., Kamm, M. A., Lichtenstein, G. R. és mtsai: Symptomatic resolution is an inadequate predictor of complete colonic mucosal healing in mild-to-moderate ulcerative colitis. Gastroenterology, 2007, 132 (Suppl.) , T1278.

    Lichtenstein G. R. , 'Symptomatic resolution is an inadequate predictor of complete colonic mucosal healing in mild-to-moderate ulcerative colitis ' (2007 ) 132 Gastroenterology : T1278 -.

    • Search Google Scholar

  • Sandborn, W. J., Rutgeerts, P., Feagan, B. G. és mtsai: Infliximab reduces colectomy in patients with moderate-to-severe ulcerative colitis: colectomy analysis from ACT 1 and ACT 2. Gut, 2007, 56 (Suppl. III) , A26.

    Feagan B. G. , 'Infliximab reduces colectomy in patients with moderate-to-severe ulcerative colitis: colectomy analysis from ACT 1 and ACT 2 ' (2007 ) 56 Gut : A26 -.

    • Search Google Scholar

  • Reinisch, W., Sandborn, W. J., Yan, S. és mtsai: Infliximab reduces UC-related hospitalizations requiring high-dose corticosteroids: the ACT trial experience in ambulatory patients with moderately to severely active UC. Gut, 2006, 55 (Suppl. V) , FP215.

    Yan S. , 'Infliximab reduces UC-related hospitalizations requiring high-dose corticosteroids: the ACT trial experience in ambulatory patients with moderately to severely active UC ' (2006 ) 55 Gut : FP215 -.

    • Search Google Scholar

  • Reinisch, W., Sandborn, W. J., Rutgeerts, P. és mtsai: Infliximab is effective as a long-term treatment for ulcerative colitis: results of the ACT long term extension. Gastroenterology, 2007, 132 (Suppl.) , O984.

    Rutgeerts P. , 'Infliximab is effective as a long-term treatment for ulcerative colitis: results of the ACT long term extension ' (2007 ) 132 Gastroenterology : O984 -.

    • Search Google Scholar

  • Thompson, H., Meissner, B., Dabbous, O. és mtsai: Infliximab is clinically effective in reducing the need for steroids in inflammatory bowel disease. Gut, 2007, 56 (Suppl III) , A129.

    Dabbous O. , 'Infliximab is clinically effective in reducing the need for steroids in inflammatory bowel disease ' (2007 ) 56 Gut : A129 -.

    • Search Google Scholar

  • Probert, C. S., Hearing, S. D., Schreiber, S. és mtsai: Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut, 2003, 52 , 998–1002.

    Schreiber S. , 'Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial ' (2003 ) 52 Gut : 998 -1002.

    • Search Google Scholar

  • Rihani, T., Otham, M. O., Hoffman, R. és mtsai: Role of infliximab in ulcerative colitis: a systematic review. Am. J. Gastroenterol., 2006, 100 (Suppl.) , O1200.

    Hoffman R. , 'Role of infliximab in ulcerative colitis: a systematic review ' (2006 ) 100 Am. J. Gastroenterol. : O1200 -.

    • Search Google Scholar

  • Casellas, F., Lopez-Vivancos, J., Vergara, M. és mtsai: Impact of inflammatory bowel disease on health-related quality of life. Dig. Dis., 1999, 17 , 208–218.

    Vergara M. , 'Impact of inflammatory bowel disease on health-related quality of life ' (1999 ) 17 Dig. Dis. : 208 -218.

    • Search Google Scholar

  • Han, S. W., McColl, E., Barton, J. R. és mtsai: Predictors of quality of life in ulcerative colitis: the importance of symptoms and illness representations. Inflamm. Bowel Dis., 2005, 11 , 24–34.

    Barton J. R. , 'Predictors of quality of life in ulcerative colitis: the importance of symptoms and illness representations ' (2005 ) 11 Inflamm. Bowel Dis. : 24 -34.

    • Search Google Scholar

  • Casellas, F., Arenas, J. I., Baudet, J. S. és mtsai: Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm. Bowel Dis., 2005, 11 , 488–496.

    Baudet J. S. , 'Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study ' (2005 ) 11 Inflamm. Bowel Dis. : 488 -496.

    • Search Google Scholar

  • Zisman, T. L., Cohen, R. D.: Pharmacoeconomics and quality of life of current and emerging biologic therapies for inflammatory bowel disease. Curr. Treat. Options Gastroenterol., 2007, 10 , 185–194.

    Cohen R. D. , 'Pharmacoeconomics and quality of life of current and emerging biologic therapies for inflammatory bowel disease ' (2007 ) 10 Curr. Treat. Options Gastroenterol. : 185 -194.

    • Search Google Scholar

  • Reinisch, W., Sandborn, W. J., Bala, M. és mtsai: Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm. Bowel Dis., 2007, 13 , 1135–1140.

    Bala M. , 'Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis ' (2007 ) 13 Inflamm. Bowel Dis. : 1135 -1140.

    • Search Google Scholar

  • Feagan, B. G., Reinisch, W., Rutgeerts, P. és mtsai: The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am. J. Gastroenterol., 2007, 102 , 794–802.

    Rutgeerts P. , 'The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients ' (2007 ) 102 Am. J. Gastroenterol. : 794 -802.

    • Search Google Scholar

  • Reinisch, W., Radford Smith, G., Bala, M. és mtsai: Steroid sparing results in further improvement in quality of life in ulcerative colitis patients in remission. Gut, 2006, 55 (Suppl. V) , G299.

    Bala M. , 'Steroid sparing results in further improvement in quality of life in ulcerative colitis patients in remission ' (2006 ) 55 Gut : G299 -.

    • Search Google Scholar

  • Jarnerot, G., Hertervig, E., Friis-Liby, I. és mtsai: Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology, 2005, 128 , 1805–1811.

    Friis-Liby I. , 'Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study ' (2005 ) 128 Gastroenterology : 1805 -1811.

    • Search Google Scholar

  • Gustavsson, A., Jarnerot, G., Hertervig, E. és mtsai: A 2-year follow-up of the Swedish–Danish infliximab/placebo trial in steroid resistant acute ulcerative colitis. Gastroenterology, 2007, 132 (Suppl.) , O983.

    Hertervig E. , 'A 2-year follow-up of the Swedish–Danish infliximab/placebo trial in steroid resistant acute ulcerative colitis ' (2007 ) 132 Gastroenterology : O983 -.

    • Search Google Scholar

  • Lees, C., Heys, D., Shand, A. G. és mtsai: Infliximab as rescue therapy in acute severe UC: a survey of the Scottish Society of Gastroenterology (SSG). Gastroenterology, 2007, 132 (Suppl.) , S1136.

    Shand A. G. , 'Infliximab as rescue therapy in acute severe UC: a survey of the Scottish Society of Gastroenterology (SSG) ' (2007 ) 132 Gastroenterology : S1136 -.

    • Search Google Scholar

  • Ferrante, M., Vermeire, S., Fidder, H. és mtsai: Short term clinical response and baseline CRP level predict colectomy after infliximab for refractory ulcerative colitis. Gut, 2007, 56 (Suppl. III) , A23.

    Fidder H. , 'Short term clinical response and baseline CRP level predict colectomy after infliximab for refractory ulcerative colitis ' (2007 ) 56 Gut : A23 -.

    • Search Google Scholar

  • Maser, E. A., Deconda, D., Lichtiger, S. és mtsai: Cyclosporine (CSA) and infliximab (INF) as acute salvage therapies for each other, in severe steroid refractory ulcerative colitis. Gastroenterology, 2007, 132 (Suppl.) , S1132.

    Lichtiger S. , 'Cyclosporine (CSA) and infliximab (INF) as acute salvage therapies for each other, in severe steroid refractory ulcerative colitis ' (2007 ) 132 Gastroenterology : S1132 -.

    • Search Google Scholar

  • Walsh, A., Cooley, R., Templeton, D. és mtsai: Acute severe ulcerative colitis: a study of predictors of outcome and efficacy for cyclosporin and infliximab. Gastroenterology, 2006, 130 (Suppl.) , O575.

    Templeton D. , 'Acute severe ulcerative colitis: a study of predictors of outcome and efficacy for cyclosporin and infliximab ' (2006 ) 130 Gastroenterology : O575 -.

    • Search Google Scholar

  • Kohn, A., Daperno, M., Armuzzi, A. és mtsai: Effectiveness and long term outcome of infliximab treatment for severe ulcerative colitis: an Italian multicentric open-label study. Gut, 2006, 55 (Suppl. V) , G185.

    Armuzzi A. , 'Effectiveness and long term outcome of infliximab treatment for severe ulcerative colitis: an Italian multicentric open-label study ' (2006 ) 55 Gut : G185 -.

    • Search Google Scholar

  • Jakobovits, S. L., Jewell, D. P., Travis, S. P. L.: Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Aliment. Pharmacol. Ther., 2007, 25 , 1055–1060.

    Travis S. P. L. , 'Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006 ' (2007 ) 25 Aliment. Pharmacol. Ther. : 1055 -1060.

    • Search Google Scholar

  • Travis, S. P. L., Stange, E. F., Lemann, M. és mtsai: European evidence-based consensus on the management of ulcerative colitis: Current management. JCC, 2008, 2 , 24–62.

    Lemann M. , 'European evidence-based consensus on the management of ulcerative colitis: Current management ' (2008 ) 2 JCC : 24 -62.

    • Search Google Scholar
Cover Orvosi Hetilap
Orvosi Hetilap
Print ISSN:
0030-6002
Online ISSN:
1788-6120
Keywords:
UC; kezelés; fulmináns; terápiarezisztens; infliximab; IBD; UC; therapy; fulminant; refractory; infliximab

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Sep 2020 3 0 0
Oct 2020 8 0 0
Nov 2020 5 3 3
Dec 2020 2 0 0
Jan 2021 0 0 0
Feb 2021 3 0 0
Mar 2021 0 0 0